PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide

European Journal of Pharmaceutical Sciences

Volumn 36, Issue 4-5, 2009, Pages 565-571

  Zimmermann, Christian ^a   van Waterschoot, Robert A B ^a   Harmsen, Stefan ^b   Maier, Angelika ^c   Gutmann, Heike ^c   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Ultrasound Unit   (Switzerland)

Author keywords

Budesonide; Cyp3a11; CYP3A4; Cytochrome P450; Dexamethasone; PXR

Indexed keywords

16ALPHA CYANOPREGNENOLONE; BUDESONIDE; CYTOCHROME P450 3A11; CYTOCHROME P450 3A4; DEXAMETHASONE; DRUG METABOLIZING ENZYME; GLUCOCORTICOID; HYDROCORTISONE; KETOCONAZOLE; LUCIFERIN; ORGANIC ANION TRANSPORTER 2; PREDNISOLONE; PREDNISONE; PREGNANE X RECEPTOR; RIFAMPICIN;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG INDICATION; DRUG METABOLISM; DRUG POTENCY; ENTERITIS; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; FIRST PASS EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; INTESTINE CELL; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; STATISTICAL ANALYSIS; TRANSACTIVATION; WILD TYPE;

ANIMALS; BUDESONIDE; CELL LINE, TUMOR; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INDUCTION; GLUCOCORTICOIDS; HUMANS; INTESTINES; LIVER; MALE; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; PROMOTER REGIONS, GENETIC; RECEPTORS, STEROID; RNA, MESSENGER;

EID: 59349085571     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.12.007     Document Type: Article

References (31)

1. Cheng X., Maher J., Dieter M.Z., and Klaassen C.D. Regulation of mouse organic anion-transporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways. Drug Metab. Dispos. 33 (2005) 1276-1282
2. Cortijo J., Urbieta E., Bort R., Castell J.V., Ruiz-Bravo C., Martinez J., Palacios-Pelaez R., Lledo S., and Morcillo E.J. Biotransformation in vitro of the 22R and 22S epimers of budesonide by human liver, bronchus, colonic mucosa and skin. Fundam. Clin. Pharmacol. 15 (2001) 47-54
3. Dilger K., Denk A., Heeg M.H., and Beuers U. No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology 41 (2005) 595-602
4. Dilger K., Alberer M., Busch A., Enninger A., Behrens R., Koletzko S., Stern M., Beckmann C., and Gleiter C.H. Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease. Aliment. Pharmacol. Ther. 23 (2006) 387-396
5. Edsbacker S., Andersson P., Lindberg C., Paulson J., Ryrfeldt A., and Thalen A. Liver metabolism of budesonide in rat, mouse, and man. Comparative aspects. Drug Metab. Dispos. 15 (1987) 403-411
6. Edsbacker S., and Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin. Pharmacokinet. 43 (2004) 803-821
7. Edsbacker S., Larsson P., and Wollmer P. Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules. Eur. J. Gastroenterol. Hepatol. 14 (2002) 1357-1362
8. Geick A., Eichelbaum M., and Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276 (2001) 14581-14587
9. Gerbal-Chaloin S., Daujat M., Pascussi J.M., Pichard-Garcia L., Vilarem M.J., and Maurel P. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J. Biol. Chem. 277 (2002) 209-217
10. Gupta A., Mugundu G.M., Desai P.B., Thummel K.E., and Unadkat J.D. Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors. Drug Metab. Dispos. 36 (2008) 1172-1180
11. Hukkanen J., Väisänen T., Lassila A., Piipari R., Anttila S., Pelkonen O., Raunio H., and Hakkola J. Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J. Pharmacol. Exp. Ther. 304 (2003) 745-752
12. Huss J.M., and Kasper C.B. Two-stage glucocorticoid induction of CYP3A23 through both the glucocorticoid and pregnane X receptors. Mol. Pharmacol. 58 (2000) 48-57
13. Jin M., Shimada T., Yokogawa K., Nomura M., Kato Y., Tsuji A., and Miyamoto K. Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone. Int. J. Pharm. 309 (2006) 81-86
14. Jonsson G., Astrom A., and Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab. Dispos. 23 (1995) 137-142
15. Lehmann J.M., McKee D.D., Watson M.A., Willson T.M., Moore J.T., and Kliewer S.A. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102 (1998) 1016-1023
16. Lin J.H., and Lu A.Y. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 35 (1998) 361-390
17. Lin J.H., Chiba M., Chen I.W., Nishime J.A., deLuna F.A., Yamazaki M., and Lin Y.J. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-450 3A [correction of P-450 A] and p-glycoprotein induction. Drug Metab. Dispos. 27 (1999) 1187-1193
18. Lu C., Hatsis P., Berg C., Lee F.W., and Balani S.K. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole. Drug Metab. Dispos. 36 (2008) 1255-1260
19. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
20. Lundin P.D., Edsbacker S., Bergstrand M., Ejderhamn J., Linander H., Hogberg L., Persson T., Escher J.C., and Lindquist B. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. Aliment. Pharmacol. Ther. 17 (2003) 85-92
21. Maier A., Zimmermann C., Beglinger C., Drewe J., and Gutmann H. Effects of budesonide on P-glycoprotein expression in intestinal cell lines. Br. J. Pharmacol. 150 (2007) 361-368
22. Moore L.B., Parks D.J., Jones S.A., Bledsoe R.K., Consler T.G., Stimmel J.B., Goodwin B., Liddle C., Blanchard S.G., Willson T.M., Collins J.L., and Kliewer S.A. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J. Biol. Chem. 275 (2000) 15122-15127
23. Pascussi J.M., Drocourt L., Fabre J.M., Maurel P., and Vilarem M.J. Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol. Pharmacol. 58 (2000) 361-372
24. Pascussi J.M., Gerbal-Chaloin S., Drocourt L., Maurel P., and Vilarem M.J. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim. Biophys. Acta 1619 (2003) 243-253
25. Schuetz J.D., Schuetz E.G., Thottassery J.V., Guzelian P.S., Strom S., and Sun D. Identification of a novel dexamethasone responsive enhancer in the human CYP3A5 gene and its activation in human and rat liver cells. Mol. Pharmacol. 49 (1996) 63-72
26. Schuetz E.G., Schmid W., Schutz G., Brimer C., Yasuda K., Kamataki T., Bornheim L., Myles K., and Cole T.J. The glucocorticoid receptor is essential for induction of cytochrome P-4502B by steroids but not for drug or steroid induction of CYP3A or P-450 reductase in mouse liver. Drug Metab. Dispos. 28 (2000) 268-278
27. Seidegård J., Nyberg L., and Borgå O. Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole. Eur. J. Pharm. Sci. 35 (2008) 264-270
28. Sheppard K.E. Nuclear receptors. II. Intestinal corticosteroid receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 282 (2002) G742-746
29. Spencer C.M., and McTavish D. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 50 (1995) 854-872
30. Thalen A., Brattsand R., and Andersson P.H. Development of glucocorticosteroids with enhanced ratio between topical and systemic effects. Acta Derm. Venereol. Suppl. (Stockh) 151 (1989) 11-19 (discussion 47-52)
31. Ufer M., Dilger K., Leschhorn L., Daufresne L., Mosyagin I., Rosenstiel P., Haesler R., Kuehbacher T., Nikolaus S., Schreiber S., and Cascorbi I. Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression. Clin. Pharmacol. Ther. 84 (2008) 43-46